Srinivas Viswanathan, Principal Investigator at Dana-Farber Cancer Institute and an Assistant Professor at Harvard Medical School, shared an article by Jiao Li, et al. on X:
“New study! ‘
Excited to share our research on translocation RCC published in Nature Metabolism, in collaboration with Liron Bar-Peled.
We reveal how the TFE3 fusion drives a key oxidative phosphorylation (OXPHOS) metabolic program in this kidney cancer.”
Oncogenic TFE3 fusions drive OXPHOS and confer metabolic vulnerabilities in translocation renal cell carcinoma.
Authors: Jiao Li, et al.
